About Us
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for developing medicines in the field of oncology – one that revolves around collaboration, shared learning, and excellence.
Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.
We have a seasoned and effective executive team steeped in science, with proven expertise across a broad range of disciplines and an unwavering commitment to delivering on our mission for patients.
Michael A. Metzger
Chief Executive Officer and Director
Luke J. Albrecht
General Counsel
Steve Closter
Chief Commercial Officer
Neil Gallagher, M.D., Ph.D.
President, Head of Research and Development
Anjali Ganguli, Ph.D.
Chief Business Officer
Keith A. Goldan
Chief Financial Officer
Kate Madigan, M.D.
Chief Medical Officer
Kevin McManus
Chief People Officer
Peter Ordentlich, Ph.D.
Chief Scientific Officer and Founder
